Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · IEX Real-Time Price · USD
10.03
+0.01 (0.10%)
Apr 16, 2024, 4:00 PM EDT - Market closed
Company Description
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.
It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.
| Country | United States |
| IPO Date | Oct 25, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 452 |
| CEO | Ms. Terrie J. Curran |
Contact Details
Address: 100 Campus Drive, Suite 102 Florham Park, New Jersey 07932 United States | |
| Phone | (877) 742-8466 |
| Website | phathompharma.com |
Stock Details
| Ticker Symbol | PHAT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001783183 |
| CUSIP Number | 71722W107 |
| ISIN Number | US71722W1071 |
| Employer ID | 82-4151574 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Terrie J. Curran | President, Chief Executive Officer and Director |
| David A. Socks | Co-Founder and Director |
| Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder and Chief Operating Officer |
| Molly Henderson CPA, MBA | Chief Financial and Business Officer |
| Dr. Aditya Kohli Ph.D. | Co-Founder |
| Lawrence R. Miller Esq., J.D. | General Counsel and Secretary |
| Tom Harris | Chief Development Sciences Officer |
| Dr. Eckhard Leifke M.D., Ph.D. | Chief Medical Officer |
| Martin J. Gilligan | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | ARS | Filing |
| Apr 10, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 13, 2024 | 8-K | Current Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |